Bleakley Financial Group LLC increased its holdings in Astrazeneca Plc (NYSE:AZN – Free Report) by 9.3% during the fourth quarter, HoldingsChannel reports. The fund owned 87,409 shares of the company’s stock after acquiring an additional 7,426 shares during the quarter. Bleakley Financial Group LLC’s holdings in Astrazeneca were worth $15,340,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Triumph Capital Management acquired a new stake in shares of Astrazeneca in the 3rd quarter worth about $25,000. Bangor Savings Bank raised its holdings in shares of Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares during the last quarter. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca in the 4th quarter worth about $30,000. Rakuten Investment Management Inc. acquired a new stake in shares of Astrazeneca in the 3rd quarter worth about $31,000. Finally, YANKCOM Partnership acquired a new stake in shares of Astrazeneca in the 4th quarter worth about $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have issued reports on AZN. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Thursday, May 14th. Weiss Ratings began coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $205.33.
Astrazeneca Stock Up 0.1%
Astrazeneca stock opened at $187.24 on Tuesday. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The firm has a 50 day moving average price of $191.60 and a 200-day moving average price of $183.22. The company has a market capitalization of $290.39 billion, a P/E ratio of 28.11, a P/E/G ratio of 1.54 and a beta of 0.26. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.
Astrazeneca (NYSE:AZN – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, equities analysts predict that Astrazeneca Plc will post 9.62 EPS for the current year.
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Articles
- Five stocks we like better than Astrazeneca
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
